Premium
C 4d‐negative antibody‐mediated rejection with high anti‐angiotensin II type I receptor antibodies in absence of donor‐specific antibodies
Author(s) -
Fuss Alexander,
Hope Christopher M,
Deayton Susan,
Bennett Greg Donald,
Holdsworth Rhonda,
Carroll Robert P,
Coates P Toby H
Publication year - 2015
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12441
Subject(s) - medicine , antibody , immunology , angiotensin ii , receptor , transplantation , kidney transplantation
Aims Acute antibody‐mediated rejection can occur in absence of circulating donor‐specific antibodies. Agonistic antibodies targeting the anti‐angiotensin II type 1 receptor (anti‐ AT 1 R ) are emerging as important non‐human leucocyte antigen ( HLA ) antibodies. Elevated levels of anti‐angiotensin II receptor antibodies were first observed in kidney transplant recipients with malignant hypertension and allograft rejection. They have now been studied in three separate kidney transplant populations and associate to frequency of rejection, severity of rejection and graft failure. Methods We report 11 cases of biopsy‐proven, C omplement 4 fragment d ( C 4d)‐negative, acute rejection occurring without circulating donor‐specific anti‐ HLA antibodies. In eight cases, anti‐angiotensin receptor antibodies were retrospectively examined. The remaining three subjects were identified from our centre's newly instituted routine anti‐angiotensin receptor antibody screening. Results All subjects fulfilled B anff 2013 criteria for antibody‐mediated rejection and all responded to anti‐rejection therapy, which included plasma exchange and angiotensin receptor blocker therapy. Conclusions These cases support the routine assessment of anti‐ AT 1 R antibodies in kidney transplant recipients to identify subjects at risk. Further studies will need to determine optimal assessment protocol and the effectiveness of pre‐emptive treatment with angiotensin receptor blockers.